Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.
Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).
Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.
Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.
Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208